Filing Overview
Registrant: MedTech Acquisition Corporation, a special purpose acquisition company (SPAC), not Trisalus Life Sciences, Inc. The Form 8-K reports events occurring on December 17, 2020 and was dated December 23, 2020.
Business Context and Reporting Period
The company completed its initial public offering (IPO) and related private placement. It had not yet completed an initial business combination, and the filing does not provide operating-period financial results.
Key Financial and Capitalization Metrics
| Item | Reported amount or terms |
|---|---|
| IPO units issued | 250,000,000 units at $10.00 per unit |
| Gross IPO proceeds | $250,000,000 |
| Public unit securities | One Class A common share and one-third of one redeemable warrant per unit |
| Public warrant exercise price | $11.50 per share per whole warrant |
| Private placement warrants | 4,933,333 warrants sold to the sponsor at $1.50 each |
| Gross private placement proceeds | $7,400,000 |
| Trust account funding | $250,000,000, consisting of $245,000,000 from the IPO and $5,000,000 from private placement proceeds |
| Trust account bank and trustee | J.P. Morgan Chase Bank, N.A.; Continental Stock Transfer & Trust Company |
| Revenue, profit, margins and cash flow | The filing does not provide operating revenue, net income, margins or cash-flow results. |
| Debt | No debt balance or debt financing is disclosed. |
Material Changes and Transactions
- The IPO and partial exercise of the underwriter’s over-allotment option closed on December 17, 2020.
- The sponsor purchased 4,933,333 private placement warrants in a transaction exempt from Securities Act registration under Section 4(a)(2).
- The company entered into underwriting, warrant, trust, sponsor, registration rights and administrative support agreements.
- The company filed an amended and restated certificate of incorporation in connection with the IPO.
Liquidity, Outlook, Risks and Contingencies
- The trust funds are restricted and generally cannot be released until an initial business combination, certain approved redemption events, or liquidation-related redemptions.
- The company must complete its initial business combination within 24 months after the IPO closing or redeem the public shares, subject to applicable law.
- Interest earned on the trust account may be available for taxes, with up to $100,000 of interest permitted for dissolution expenses.
- The filing provides no business-combination target, operating guidance or forecast.
- Investor returns may be affected by public-share redemptions, warrant exercise terms, sponsor interests and the risk that no qualifying business combination is completed.
Important Facts to Verify
- Confirm that the filing relates to MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Review the trust agreement and certificate of incorporation for redemption rights, liquidation provisions and the 24-month deadline.
- Verify the final number of public shares, warrants and any over-allotment securities issued.
- Review the warrant agreement for dilution, redemption and exercise provisions.
- Reconcile the $5,000,000 of private-placement proceeds deposited into the trust account with the $7,400,000 gross private placement proceeds disclosed in the filing.